Brian Malik, Ph.D. is a Senior Analyst at Catalio Capital Management, LP. He is primarily responsible for making private equity investments in breakthrough biomedical technology companies founded by leading scientist-entrepreneurs.
Prior to joining Catalio, Brian was a Vice President at T. Rowe Price, a global investment manager, where he focused on public equity investments in small- and mid-cap biotech companies. Prior to that, Brian was an Associate at JDRF T1D Fund, a venture philanthropy fund, where he was responsible for early-stage private investments in companies pursuing type 1 diabetes. Earlier, he was a Consultant at Artisan Healthcare Consulting where he provided strategic insights for drug development to pharma and biotech clients.
Brian earned his Ph.D. in Microbiology & Immunology from Dartmouth College. His thesis research was focused on the role of resident memory T cells in cancer and autoimmune disease. He received his B.S. in Cell Biology / Biochemistry from Bucknell University.